Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc.
private/Beacon Topco, Inc.CLYDBarinthus Bio and Clywedog to merge with Beacon Topco in stock deal
Deal value
—
stock
Per-share offer
—
Premium
—
Days to close
—
Term fee
—
No structured deal economics extracted yet. Re-run the scanner or fall back to the source filing below.
Announced
Apr 24, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
—
No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.
No closing-condition data extracted.
No competing-bidder, activist, or dissident-proxy signals in the database for this target.
Acquirer side· Beacon Topco, Inc.
Legal
- · Robert Puopolo
- · Blake Liggio
- · Jean Lee
“Robert Puopolo, Esq.Blake Liggio, Esq.Jean Lee, Esq.Goodwin Procter LLP100 Northern AvenueBoston, MA 02210(617) 570-1000”
Target side· Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc.
Legal
- · Bardia Moayedi
- · Christopher L. Tinen
- · Sarah A. Hibbard
“Bardia Moayedi, Esq.Christopher L. Tinen, Esq.Sarah A. Hibbard, Esq.Snell & Wilmer L.L.P.3611 Valley Centre Drive, Suite 500San Diego, CA 92130(858) 910-4809”
| Firm | Role | Side | Deals in DB | |
|---|---|---|---|---|
| Goodwin Procter LLP | Legal | Acquirer | 7 | View deals → |
| Snell & Wilmer L.L.P. | Legal | Target | 2 | View deals → |
- Apr 24, 2026this filing
Barinthus Bio and Clywedog to merge with Beacon Topco in stock deal
Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc. entered into a Merger Agreement with Beacon Topco, Inc. to create a combined company advancing clinical-stage candidates targeting metabolic and autoimmune diseases. The transaction involves a scheme of arrangement for Barinthus Bio shareholders and a merger for Clywedog shareholders, with Barinthus Bio shareholders expected to own approximately 34% and Clywedog stockholders approximately 66% of the combined entity on a fully diluted basis. The combined company will be renamed Clywedog Therapeutics Holdings, Inc. and listed on Nasdaq under ticker symbol CLYD.